Trial Profile
A PROSPECTIVE RANDOMIZED PHASE II STUDY EVALUATING THE OPTIMIZATION OF THE RESIDUAL PLASMATIC LEVEL OF DASATINIB (SPRYCEL) IN PATIENTS NEWLY DIAGNOSED WITH CHRONIC PHASE CHRONIC MYELOGENOUS LEUKAEMIA (CP-CML)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Jan 2022
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Adverse reactions
- Acronyms OPTIM-DASA
- 17 Jun 2018 Results of a retrospective study assessing maintenance therapy with dasatinib every other day in CP-CML patients along with the results of a prospective maintenance study which is a part of OPTIM dasatinib trial, presented at the 23rd Congress of the European Haematology Association.
- 14 Jun 2015 Results of STOP substudy presented at the 20th Congress of the European Haematology Association.
- 15 Apr 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.